- Home
- NERV vs IBIO Comparison
NERV vs IBIO Comparison
Compare NERV & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- IBIO
- Stock Information
- Founded
- NERV 2007
- IBIO 2008
- Country
- NERV United States
- IBIO United States
- Employees
- NERV N/A
- IBIO N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- NERV Health Care
- IBIO Health Care
- Exchange
- NERV Nasdaq
- IBIO Nasdaq
- Market Cap
- NERV 12.0M
- IBIO 11.9M
- IPO Year
- NERV 2014
- IBIO N/A
- Fundamental
- Price
- NERV $2.25
- IBIO $0.74
- Analyst Decision
- NERV Hold
- IBIO Strong Buy
- Analyst Count
- NERV 1
- IBIO 2
- Target Price
- NERV $5.00
- IBIO $5.50
- AVG Volume (30 Days)
- NERV 35.1K
- IBIO 552.7K
- Earning Date
- NERV 08-14-2025
- IBIO 09-19-2025
- Dividend Yield
- NERV N/A
- IBIO N/A
- EPS Growth
- NERV N/A
- IBIO N/A
- EPS
- NERV 1.48
- IBIO N/A
- Revenue
- NERV N/A
- IBIO $375,000.00
- Revenue This Year
- NERV N/A
- IBIO $81.33
- Revenue Next Year
- NERV N/A
- IBIO N/A
- P/E Ratio
- NERV $1.52
- IBIO N/A
- Revenue Growth
- NERV N/A
- IBIO 650.00
- 52 Week Low
- NERV $1.15
- IBIO $0.56
- 52 Week High
- NERV $3.00
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- NERV 69.92
- IBIO 55.49
- Support Level
- NERV $1.79
- IBIO $0.56
- Resistance Level
- NERV $1.81
- IBIO $0.78
- Average True Range (ATR)
- NERV 0.10
- IBIO 0.06
- MACD
- NERV 0.01
- IBIO 0.01
- Stochastic Oscillator
- NERV 76.56
- IBIO 72.48
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.